Effect of food on the pharmacokinetics of Olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors.
Authors
Rolfo, CSwaisland, H
Leunen, K
Rutten, A
Soetekouw, P
Slater, S
Verheul, H
Fielding, A
So, K
Bannister, W
Dean, Emma J
Affiliation
Univ Antwerp Hosp, Dept Oncol, Early Clin Trials Unit, B-2650 Edegem, BelgiumIssue Date
2015-06
Metadata
Show full item recordAbstract
The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer.Citation
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. 2015, 32 (6):510-22 Adv TherJournal
Advances in TherapyDOI
10.1007/s12325-015-0214-4PubMed ID
26048134Type
ArticleLanguage
enISSN
1865-8652ae974a485f413a2113503eed53cd6c53
10.1007/s12325-015-0214-4
Scopus Count
Collections
Related articles
- Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
- Authors: Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR
- Issue date: 2015 Oct
- Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
- Authors: Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R
- Issue date: 2016 Oct
- A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
- Authors: Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X, Tamura T
- Issue date: 2012 Mar
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
- Authors: Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, Cassidy J
- Issue date: 2012 Aug
- Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
- Authors: Swaisland H, Plummer R, So K, Garnett S, Bannister W, Fabre MA, Dota C, Fielding A
- Issue date: 2016 Oct